Medicare has added Botox to its list of drugs eligible for price negotiation under the Inflation Reduction Act, alongside 14 other medications. The move marks the first time a major neuromodulator has entered the payer-negotiation process, signaling CMS's intent to constrain costs on one of aesthetic medicine's highest-volume injectables.